Showing results (51-60 of 63) with videos related to
Sort By:
Pageof 7
Journal of Medicinal Chemistry|May 16, 2013
Fragment-based ligand design of novel potent inhibitors of tankyrasesE Andreas Larsson, Anna Jansson, Fui Mee Ng, et al.Journal of Medicinal Chemistry|May 25, 2011
Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphomaAnthony D William, Angeline C-H Lee, Stéphanie Blanchard, et al.Journal of Medicinal Chemistry|July 4, 2017
Scaffold Hopping and Optimization of Maleimide Based Porcupine InhibitorsSoo Yei Ho, Jenefer Alam, Duraiswamy Athisayamani Jeyaraj, et al.Angewandte Chemie (International Ed. in English)|April 28, 2020
Discovery of a Novel Mycobacterial F-ATP Synthase Inhibitor and its Potency in Combination with DiarylquinolinesAdam Hotra, Priya Ragunathan, Pearly Shuyi Ng, et al.Proceedings of the National Academy of Sciences of the United States of America|July 7, 2018
Targeting cancer addiction for SALL4 by shifting its transcriptome with a pharmacologic peptideBee Hui Liu, Chacko Jobichen, C S Brian Chia, et al.Bioorganic & Medicinal Chemistry|October 2, 2021
Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitorsPearly Shuyi Ng, Klement Foo, Sandra Sim, et al.Journal of Medicinal Chemistry|April 25, 2018
Fragment-Based Drug Discovery of Potent Protein Kinase C Iota InhibitorsJacek Kwiatkowski, Boping Liu, Doris Hui Ying Tee, et al.Journal of Medicinal Chemistry|March 25, 2016
Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic CellsJoseph Cherian, Kassoum Nacro, Zhi Ying Poh, et al.Journal of Medicinal Chemistry|January 8, 2020
Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2Jacek Kwiatkowski, Boping Liu, Shermaine Pang, et al.Journal of Medicinal Chemistry|June 4, 2011
Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profileHaishan Wang, Niefang Yu, Dizhong Chen, et al.Pageof 7